Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces its unaudited interim results for the six months ended 30 September 2020.
·
Dr Huw Jones appointed as Chief Executive Officer
·
Completion of first out-licensing deal with Juvenescence for use of Sulforadex® technology in non-pharmaceutical markets. Up to $10.5m receivable in milestones with royalties on sales
·
Phase IIb/III trial using SFX-01 for
acute respiratory distress syndrome ("
ARDS") including COVID-19 patients sponsored by Dundee University, with grant funding from LifeArc; the ''STAR'' trial (
SFX-01 treatment for acute respiratory infections)
·
Patient recruitment commenced in STAR trial post the period end with data potentially available in Q4 2021.